文献速递头颈外科

覆膜支架治疗头颈癌患者颈动脉破裂综合征

Covered Stent Graft for Treatment of Carotid Blowout Syndrome in Patients With Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项在法国Gustave Roussy研究所开展的病例系列研究,回顾了2006年1月至2021年12月间62例头颈癌合并颈动脉破裂综合征(CBS)患者共67次支架置入手术。即刻止血率100%,但再出血(16例,38.8%)和卒中(9例,13.4%)常见,30天生存率77.3%,中位总生存59天。急性CBS表现和BMI与30天死亡率独立相关。

要点

  • 覆膜支架治疗CBS即刻止血率100%,但再出血和卒中风险较高。
  • 30天生存率77.3%,中位总生存期59天,预后仍差。
  • 急性CBS表现和较低BMI与30天死亡风险升高相关。

核心结论

  • 覆膜支架可安全处理CBS并保持颈动脉通畅,但存在显著的缺血和再出血风险。
  • 作者认为支架移植物应仅用于特定临床场景。
  • 尽管止血技术成功率高,但总体和30天生存结局凸显CBS在癌症患者中的严重后果和治疗挑战。

研究设计与样本

  • 法国Villejuif的Institut Gustave Roussy单中心病例系列研究,纳入2006年1月至2021年12月期间所有因CBS转诊接受血管内治疗的符合条件的头颈癌患者。
  • 共62例患者(平均年龄55.4岁,SD 10.1;女性10例[16.1%],男性52例[83.9%]),接受67次CBS相关支架置入手术。
  • 从医疗记录中回顾性收集危险因素及围手术期和术后数据,数据分析于2022年7月至2024年7月进行。

主要发现

  • 最常见的临床并发症为再出血(16例患者[38.8%])和卒中(9例患者[13.4%])。
  • 即刻止血在100%的病例中实现。
  • 术后30天生存率为77.3%(51例参与者),中位总生存时间(IQR)为59(32-141.5)天。
  • 单变量分析中,急性CBS表现(风险比4.30;95%CI 1.11-28.23)和BMI(风险比0.88;95%CI 0.77-0.99)与30天死亡率有统计学显著关联。

关键数值与推荐

  • 技术成功定义为即刻控制出血,本研究中为100%。
  • 主要结局为支架置入的围手术期和术后并发症;次要结局为技术成功、30天和总体生存率以及死亡和再出血的危险因素。
  • 考虑的危險因素包括体重指数(BMI)、CBS表现、血流动力学状态、肿瘤分期和放射剂量。

临床怎么用

  • 作者认为覆膜支架应仅用于特定临床场景。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Carotid blowout syndrome (CBS) is a rare life-threatening complication of head and neck cancer that requires either surgical or endovascular treatment such as a carotid occlusion procedure or stent-graft placement. CBS outcomes and complications of its management using endovascular stent-graft placement remain unclear due to limited published data. Given that this treatment approach is increasingly used, understanding its efficacy and associated risks is paramount. OBJECTIVE: To evaluate the periprocedural and postprocedural complications and outcomes associated with stent-graft treatment for CBS in patients with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: This case series study conducted at the Institut Gustave Roussy (Villejuif, France) between January 2006 and December 2021 included all eligible patients with head and neck cancer who experienced CBS and were referred for endovascular treatment. Risk factors and periprocedural and postprocedural data were collected retrospectively from medical records. Data analyses were performed from July 2022 to July 2024. EXPOSURE: Endovascular stent-graft placement for the treatment of CBS in patients with head and neck cancer. MAIN OUTCOMES AND MEASURES: Periprocedural and postprocedural complications of stent-graft placement. Secondary outcomes were technical success, defined as immediate control of hemorrhage; 30-day and overall survival rates; and risk factors for mortality and rebleeding. Risk factors considered were body mass index (BMI), CBS presentation, hemodynamic status, tumor stage, and radiation dose. RESULTS: In all, 67 CBS-related stent-graft procedures were performed in 62 patients (mean [SD] age, 55.4 [10.1] years; 10 [16.1%] females and 52 [83.9%] males), most with advanced-stage head and neck cancer, over 15 years. The most frequently observed clinical complications were rebleeding (16 patients [38.8%]) and stroke (9 patients [13.4%]). Immediate hemostasis was achieved in 100% of cases. The survival rate was 77.3% (51 participants) at 30 days postprocedure, with a median (IQR) overall survival time of 59 (32-141.5) days. Acute CBS presentation (risk ratio, 4.30; 95% CI, 1.11-28.23) and BMI (risk ratio, 0.88; 95% CI, 0.77-0.99) showed a statistically significant association with 30-day mortality in univariate analysis. CONCLUSIONS AND RELEVANCE: The findings of the case-series study indicate that CBS can be safely managed with endovascular stent-graft placement that preserves carotid patency; however, it carries significant risks of ischemia and rebleeding. These findings suggest that stent grafts should be used only in specific clinical scenarios. Despite achieving a high rate of technical success in controlling hemorrhage, the overall and 30-day survival outcomes underscore the critical implications of CBS in patients with cancer and its associated therapeutic challenges.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Plaforet V, Tournier L, Deschamps F, et al. Covered Stent Graft for Treatment of Carotid Blowout Syndrome in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39361294. doi:10.1001/jamaoto.2024.3228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。